How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention.
作者信息
Rodriguez Fatima, Khera Amit
机构信息
Department of Internal Medicine, Division of Cardiology and the Cardiovascular Institute, Stanford University, CA (F.A.).
Department of Internal Medicine, Division of Cardiology, UT Southwestern Medical Center, Dallas, TX (A.K.).
出版信息
Circulation. 2023 Apr 18;147(16):1204-1207. doi: 10.1161/CIRCULATIONAHA.123.064041. Epub 2023 Apr 17.
Abstract
摘要
相似文献
1
How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention.
Circulation. 2023 Apr 18;147(16):1204-1207. doi: 10.1161/CIRCULATIONAHA.123.064041. Epub 2023 Apr 17.
2
Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids).
J Am Coll Cardiol. 2013 Nov 19;62(21):1960-1965. doi: 10.1016/j.jacc.2013.07.045. Epub 2013 Aug 21.
3
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
N Engl J Med. 1999 Aug 5;341(6):410-8. doi: 10.1056/NEJM199908053410604.
4
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003.
5
Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.
Heart Vessels. 2014 Jan;29(1):35-41. doi: 10.1007/s00380-013-0330-5. Epub 2013 Mar 21.
6
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Metabolism. 2008 Jun;57(6):796-801. doi: 10.1016/j.metabol.2008.01.026.
7
Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
BMC Cardiovasc Disord. 2017 Jan 5;17(1):10. doi: 10.1186/s12872-016-0450-9.
8
Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
JAMA. 2017 Jan 24;317(4):439-440. doi: 10.1001/jama.2016.19061.
9
Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
JAMA. 2017 Jan 24;317(4):439. doi: 10.1001/jama.2016.19058.
10
Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply.
JAMA. 2017 Jan 24;317(4):440. doi: 10.1001/jama.2016.19064.
引用本文的文献
1
Inflammation in atherosclerosis: a Big Idea that has underperformed so far.
Curr Opin Lipidol. 2025 Apr 1;36(2):78-87. doi: 10.1097/MOL.0000000000000973. Epub 2025 Jan 22.
2
The association between vitamin E intake and remnant cholesterol, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in US adults: a cross-sectional study.
Lipids Health Dis. 2024 Oct 1;23(1):325. doi: 10.1186/s12944-024-02313-8.
本文引用的文献
1
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
Circulation. 2023 Apr 18;147(16):1192-1203. doi: 10.1161/CIRCULATIONAHA.122.063399. Epub 2023 Feb 13.
2
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.
J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25.
3
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
4
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.
5
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
6
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.
JAMA Cardiol. 2018 Aug 1;3(8):749-753. doi: 10.1001/jamacardio.2018.1533.
7
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.
8
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
9
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
JAMA Cardiol. 2017 May 1;2(5):547-555. doi: 10.1001/jamacardio.2017.0083.
10
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
Zotero 插件